Riverstone HoldingsSGX:AP4 +0.61%63 EBITDA Margin % is 33.45% as of Dec. 2025, which is 6% below its 10-year median of 35.46. GuruFocus rates SGX:AP4 with a GF Score™ of 63/100 and a GF Value™ of S$0.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Riverstone Holdings ranks better than 93.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Riverstone Holdings's EBITDA for the
three
months ended in Dec. 2025 was S$26.5 Mil. Riverstone Holdings's Revenue for the
three
months ended in Dec. 2025 was S$79.2 Mil. Therefore, Riverstone Holdings's EBITDA margin for the quarter that ended in Dec. 2025 was 33.45%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Riverstone Holdings EBITDA Margin % Related Terms
Riverstone Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Riverstone Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:AP4 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Riverstone Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Riverstone Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Riverstone Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Riverstone Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Riverstone Holdings (SGX:AP4) has a EBITDA Margin % of 33.45% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Riverstone Holdings and its competitors. This is near median its historical median of 35.46. Over the past decade, Riverstone Holdings' EBITDA Margin % has ranged from 20.83 to 62.11. According to the industry distribution chart, Riverstone Holdings ranks #53 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 6.5%.
Is Riverstone Holdings' EBITDA Margin % too high?
Riverstone Holdings' current EBITDA Margin % of 33.45% is near median its 10-year median of 35.46. Over the past 10 years, this metric has ranged from a low of 20.83 to a high of 62.11. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Riverstone Holdings' value of 33.45% is 347.5% above this industry median. Based on the distribution chart, Riverstone Holdings ranks #53 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Riverstone Holdings has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Riverstone Holdings' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Riverstone Holdings ranks #53 out of 816 companies for EBITDA Margin %. This places Riverstone Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Riverstone Holdings' value of 33.45% is 347.5% above this benchmark. Historically, Riverstone Holdings' own EBITDA Margin % has ranged from 20.83 to 62.11 over the past decade. While the company's 10-year median is 35.46 vs. the industry median of 7.48, Riverstone Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Riverstone Holdings's current EBITDA Margin % of 33.45% is 347.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Riverstone Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Riverstone Holdings's current EBITDA Margin % is 33.45%, which is near median its own 10-year median of 35.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Riverstone Holdings stock overvalued right now?
Based on GuruFocus' analysis, Riverstone Holdings (SGX:AP4) is currently considered Fairly Valued. The stock's GF Value™ is S$0.86, compared to a current price of S$0.83 — trading 3.5% below its estimated fair value. The current EBITDA Margin % is 33.45%, which is near median its 10-year median of 35.46 and 347.5% above the Medical Devices & Instruments industry median of 7.48. Riverstone Holdings' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Riverstone Holdings (SGX:AP4), the current EBITDA Margin % is 33.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Riverstone Holdings (SGX:AP4) Overvalued in 2026?
Based on GuruFocus' analysis, Riverstone Holdings stock appears to be undervalued.
The current stock price of S$0.83 is trading 3.5% below its estimated GF Value™ of S$0.86.
GuruFocus considers Riverstone Holdings to be Fairly Valued.
Key valuation signals for SGX:AP4:
EBITDA Margin %: 33.45% (near median its 10-year median of 35.46)
GF Value™: S$0.86 vs. price of S$0.83 (3.5% below fair value)
Industry Position: 347.5% above the Medical Devices & Instruments median (#53 of 816)
No single metric tells the full story. See the SGX:AP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Riverstone Holdings Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the manufacture and sales of gloves and non-glove consumables such as finger cots, static shielding bags, face masks, wipers, and packaging materials. The group's products are widely qualified and used in the Hard Disk Drive, and semiconductor industries. It operates in three segments based on its geography: Malaysia, Thailand, China, Singapore, and Others, of which the majority of its revenue comes from Malaysia.
63GF Score
Get the complete analysis for SGX:AP4
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:AP4 has been successfully added to your 
